Patents by Inventor Nikolina Vlatkovic

Nikolina Vlatkovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated antibody specific for a mammalian MDM2 binding protein comprising SEQ ID No. 2 or 4
    Patent number: 7732577
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 8, 2010
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Thomas Boyd, Dale Stewart Haines, Nikolina Vlatkovic
  • Mammalian MDM2 Binding Proteins and Uses Thereof
    Publication number: 20090017538
    Abstract: Isolated nucleic acid sequences encoding mammalian binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Application
    Filed: October 23, 2007
    Publication date: January 15, 2009
    Inventors: Mark Thomas Boyd, Dale Stewart Haines, Nikolina Vlatkovic
  • Cancer Treatment
    Publication number: 20080085279
    Abstract: The present invention relates to the inhibitors of MDM2 Binding Protein (MTBP) activity that may be used as medicaments. Such medicaments may be used to prevent or treat cancers. A preferred inhibitor is an siRNA molecule that is specific for silencing MTBP expression. The invention further relates to screening methods (e.g. for identifying MTBP inhibitors that may be used to treat cancers).
    Type: Application
    Filed: December 22, 2005
    Publication date: April 10, 2008
    Applicant: University of Liverpool
    Inventors: Mark Boyd, Nikolina Vlatkovic, Mark Brady
  • Mammalian MDM2 binding proteins
    Patent number: 7304142
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: December 4, 2007
    Assignee: Philadelphia, Health and Education Corporation
    Inventors: Mark Thomas Boyd, Dale Stewart Haines, Nikolina Vlatkovic
  • Mammalian MDM2 binding proteins and uses thereof
    Publication number: 20070129324
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 7, 2007
    Inventors: Mark Boyd, Dale Haines, Nikolina Vlatkovic
  • Mammalian MDM2 binding proteins and uses thereof
    Patent number: 7166712
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 23, 2007
    Assignee: Philadelphia, Health and Education Corporation
    Inventors: Mark Thomas Boyd, Dale Stewart Haines, Nikolina Vlatkovic
  • Mammalian mdm2 binding proteins and uses thereof
    Publication number: 20050277764
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Application
    Filed: July 12, 2001
    Publication date: December 15, 2005
    Inventors: Mark Boyd, Dale Haines, Nikolina Vlatkovic